Table 1.
Characteristics of patients included in the study.
| Parameters | Value of parameters in the groups | ||
|---|---|---|---|
| PAPS, | SLE + APS, | SLE, | |
| n = 20 | n = 26 | n = 39 | |
| Mean age, year ± SD | 34.0 ± 10.8 | 40.0 ± 11.8 | 35.5 ± 13.1 |
|
| |||
| Disease duration, year ± SD | 8.1 ± 7.3 | 16.0 ± 11.6∗∗ | 10.2 ± 10.0 |
|
| |||
| Females/males, n (%) | 12 (60)/8 (40) | 22 (85)/4 (15) | 36 (92)/3 (8) |
|
| |||
| Disease activity, SLEDAI-index (mean scores ± SD) | - | 19.4 ± 8.6 | 20.0 ± 12.1 |
|
| |||
| Thrombosis in past history, n (%) | 16 (80) | 18 (69) | - |
|
| |||
| Obstetrical morbidity, n (%)∗ | 5 (20) | 11 (42.3) | - |
|
| |||
| Therapy at the time of study inclusion | |||
|
| |||
| GCs, n (%) | 0 | 23 (89) | 21 (54) |
|
| |||
| Anticoagulants (LMWH, VKA), n (%) | 20 (100) | 26 (100) | 3 (7.7) |
|
| |||
| LDASA, n (%) | 20 (100) | 26 (100) | 14 (36) |
|
| |||
| NSAID, n (%) | 1 (5) | 9 (34.6) | 10 (25.6) |
|
| |||
| Patients [n (%)] who did not receive GCs, ACs, LDASA, NSAID+LDASA (comparison group) during 6 months or more | - | - | 12 (30.8) |
Note: SD: standard deviations; GCs: glucocorticoids; LDASA: low-dose acetylsalicylic acid; NSAID: nonsteroidal anti-inflammatory drugs; ACs: anticoagulants; LMWH: low-molecular-weight heparin; VKA: vitamin K antagonist.
∗ The percentage was calculated from the number of women who had a pregnancy during the disease.
∗∗P < 0.005 compared to those in PAPS patients.